Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Jen Lee

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Cancer Immunology, Immunotherapy : CII|February 8, 2008
Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1)Jung Hee Woo, Sarah H Bour, Tony Dang, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirGuofeng Cheng, Yang Tian, Brian Doehle, et al.
International Journal of Molecular Sciences|March 14, 2026
Pathway-Level Convergence Between Dynamic Plasma miRNAs and Endometrial Biological Processes During the Human Peri-Implantation WindowChun-I Lee, An Hsu, Yu-Jen Lee, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infectionScott E Lazerwith, Willard Lew, Jennifer Zhang, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymeraseMartijn Fenaux, Stacey Eng, Stephanie A Leavitt, et al.
Journal of Medicinal Chemistry|January 12, 2017
Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin AVictoria A Steadman, Simon B Pettit, Karine G Poullennec, et al.
Journal of Medicinal Chemistry|August 4, 2018
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin MacrocycleRichard L Mackman, Victoria A Steadman, David K Dean, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Cancer Immunology, Immunotherapy : CII|February 8, 2008
Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1)Jung Hee Woo, Sarah H Bour, Tony Dang, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2016
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor LedipasvirGuofeng Cheng, Yang Tian, Brian Doehle, et al.
International Journal of Molecular Sciences|March 14, 2026
Pathway-Level Convergence Between Dynamic Plasma miRNAs and Endometrial Biological Processes During the Human Peri-Implantation WindowChun-I Lee, An Hsu, Yu-Jen Lee, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2019
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi<sup>®</sup> and Epclusa<sup>®</sup>John O Link, James G Taylor, Alejandra Trejo-Martin, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2014
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrugJoy Y Feng, Guofeng Cheng, Jason Perry, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infectionScott E Lazerwith, Willard Lew, Jennifer Zhang, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymeraseMartijn Fenaux, Stacey Eng, Stephanie A Leavitt, et al.
Journal of Medicinal Chemistry|January 12, 2017
Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin AVictoria A Steadman, Simon B Pettit, Karine G Poullennec, et al.
Journal of Medicinal Chemistry|August 4, 2018
Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin MacrocycleRichard L Mackman, Victoria A Steadman, David K Dean, et al.
Pageof 5